Motivated by recent presentation of the KEYNOTE-564 interim results for adjuvant pembrolizumab in clear-cell renal cell carcinoma, we discuss concepts that can guide patient-specific decision-making in selecting individuals for whom adjuvant therapies should be offered.
European urology oncology. 2021 Sep 21 [Epub ahead of print]
Pavlos Msaouel, Petros Grivas, Tian Zhang
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ., Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA., Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, TX, USA; Division of Medical Oncology, Duke Department of Medicine, Durham, NC, USA; Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC, USA.